Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia.
Blood Rev
; 66: 101208, 2024 Jul.
Article
en En
| MEDLINE
| ID: mdl-38734488
ABSTRACT
There have been major paradigm shifts in the treatment of Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in the last decade with the introduction of new immunotherapies and targeted agents, adoption of pediatric-type chemotherapy protocols in younger adults as well as chemotherapy light approaches in older adults and the incorporation of measurable residual disease (MRD) testing to inform clinical decision making. With this, treatment outcomes in adult Ph- ALL have improved across all age groups. However, a subset of patients will still develop relapsed disease, which can be challenging to treat and associated with poor outcomes. Here we review the treatment of Ph- ALL in both younger and older adults, including the latest advancements and future directions.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Cromosoma Filadelfia
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
Límite:
Humans
Idioma:
En
Revista:
Blood Rev
/
Blood rev
/
Blood reviews
Asunto de la revista:
HEMATOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos